New blood pressure drug aims for Round-the-Clock control

NCT ID NCT06174766

Completed Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This clinical trial is testing a new medication called HGP2102 for people with essential hypertension, or high blood pressure. The study compares HGP2102 to a control drug to see how well it lowers blood pressure over a full 24-hour period. Participants are adults with high blood pressure who meet specific blood pressure criteria. The goal is to determine if HGP2102 is safe and effective for managing this common condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HGP2102
What this could lead to: If successful, HGP2102 could offer a new treatment option for people with high blood pressure, potentially improving blood pressure control.
What could go wrong: This is a phase 3 trial, so while promising, the drug may not prove more effective than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Show contact details

Locations

Sevrance hosptal

Seodaemun-gu, Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.